|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||132.94 - 133.25|
|52-week range||104.50 - 143.90|
|Beta (5Y monthly)||0.17|
|PE ratio (TTM)||104.10|
|Forward dividend & yield||2.80 (2.10%)|
|Ex-dividend date||11 Aug 2022|
|1y target est||N/A|
Clovis Oncology (CLVS) tanks in the past six months following the possibility of a bankruptcy filing in the near term.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
WILMINGTON, Del., November 22, 2022--AstraZeneca will present new data advancing its ambition to redefine care at the 2022 San Antonio Breast Cancer Symposium (SABCS), December 6-10, 2022.